Related references
Note: Only part of the references are listed.Feasibility of Bronchial Washing Fluid-Based Approach to Early-Stage Lung Cancer Diagnosis
Jeong-Seon Ryu et al.
ONCOLOGIST (2019)
Current and future perspectives of liquid biopsies in genomics-driven oncology
Ellen Heitzer et al.
NATURE REVIEWS GENETICS (2019)
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
Zuan-Fu Lim et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients
S. Valpione et al.
EUROPEAN JOURNAL OF CANCER (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
Jae Young Hur et al.
MOLECULAR CANCER (2018)
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer
Suzanne Jenkins et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review)
Kaidi Li et al.
ONCOLOGY REPORTS (2017)
Assessment of real-time PCR method for detection of EGFR mutation using both supernatant and cell pellet of malignant pleural effusion samples from non-small-cell lung cancer patients
Saeam Shin et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2017)
Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid
Sojung Park et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2017)
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
Cloud P. Paweletz et al.
CLINICAL CANCER RESEARCH (2016)
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
Karen L. Reckamp et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing
Ke-Zhong Chen et al.
SCIENTIFIC REPORTS (2016)
Fragment Length of Circulating Tumor DNA
Hunter R. Underhill et al.
PLOS GENETICS (2016)
Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer
Adrian G. Sacher et al.
JAMA ONCOLOGY (2016)
Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
A. Szpechcinski et al.
BRITISH JOURNAL OF CANCER (2015)
Epidermal Growth Factor Receptor Mutation Status in Cell-Free DNA Supernatant of Bronchial Washings and Brushings
Akihiko Kawahara et al.
CANCER CYTOPATHOLOGY (2015)
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
Chee-Seng Tan et al.
LANCET ONCOLOGY (2015)
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
Kenneth S. Thress et al.
LUNG CANCER (2015)
Gefitinib Treatment in EGFR Mutated Caucasian NSCLC Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
Jean-Yves Douillard et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Detection of EGFR mutational profile by direct dideoxy sequencing in cytology and non-cytology biopsy samples
Connull Leslie et al.
PATHOLOGY (2014)
High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas
Ping-Li Sun et al.
CANCER CYTOPATHOLOGY (2013)
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Neal I. Lindeman et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients
Xiao Zhao et al.
RESPIRATION (2013)
Epidermal Growth Factor Receptor Gene Analysis With a Highly Sensitive Molecular Assay in Routine Cytologic Specimens of Lung Adenocarcinoma
Sara Allegrini et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
Koichi Goto et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
EGFR Mutations and Lung Cancer
Gilda da Cunha Santos et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing
Natasha Rekhtman et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Bronchoscopy in Lung Cancer Appraisal of Current Technology and for the Future
Pyng Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Endobronchial ultrasonography with guide-sheath for peripheral pulmonary lesions
E Kikuchi et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
Endobronchial ultrasonography using a guide sheath increases the ability to diagnose peripheral pulmonary lesions endoscopically
N Kurimoto et al.
CHEST (2004)
Quantification of free circulating DNA as a diagnostic marker in lung cancer
G Sozzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
